# Edibeck Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edibeck-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.edibeck.cn
- Latest round: Series A (Dec 23, 2025)
- Investors on record: 2

## About

Based in Shenzhen, China, and founded in 2023, Shenzhen Aidibeike Biopharmaceutical Co., Ltd., doing business as Edibeck Therapeutics, is a drug discovery company that focuses on CRISPR gene-editing technology. The company holds multiple patents on CRISPR gene-editing. Its founder and CEO, Mr. Zhenhuang Yang, graduated from University of Lübeck/UKSH, Germany and is an associate researcher at Nanjing Gulou Hospital.

In February 2024, the company closed an angel funding led by Cowin Capital. In December 2025, Edibeck Therapeutics closed series A+ funding from returning investor Cowin Capital.

Edibeck Therapeutics is committed to the development of gene-based therapies, focusing on the research and application of foundational gene editing technologies, particularly in Type I CRISPR technology which has been applied to virus removal. The company generates revenue from developing drugs and therapies based on gene-editing technology.

The series A+ funding will be used by the company to advance technology transfer and new drug development.

## Funding rounds

- Series A, Dec 23, 2025 — Cowin Capital
- Angel, Feb 1, 2024 — Cowin Capital, Entropy Capital

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Angel, Series A
- Entropy Capital (https://capitalatlas.ai/funds/entropy-capital) — Angel